Caitong International Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Caitong International Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3	Buy	+1	New	+$6	﹤0.01%	2389

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Caitong International Asset Management's IMDX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Insight Molecular Diagnostics (IMDX) in Q1 2026: 1 share worth $3. The stake represents ﹤0.01% of the portfolio and ranks #2389 among its holdings.

41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

Caitong International Asset Management held 1 share of Insight Molecular Diagnostics worth $3 as of Q1 2026.
Insight Molecular Diagnostics was a new Caitong International Asset Management position in Q1 2026.
Insight Molecular Diagnostics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2389 holding.
41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.